Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 2/20 | 0.42 |
| ▸ | SPHK1 | Q9NYA1 | 10/20 | 0.40 |
| ▸ | THRA | P10827 | 1/20 | 0.38 |
| ▸ | RARB | P10826 | 5/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | RARA | P10276 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SPHK2 | Q9NRA0 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21074598 | 0.92 | SPHK1 (0.41) | THRBSPHK1THRAFFAR4SPHK2 | |
| SCHEMBL21074601 | 0.91 | FFAR4 (0.38) | THRBSPHK1THRARARBFFAR4 | |
| SCHEMBL21074610 | 0.89 | THRB (0.42) | THRBTHRARARBMEN1ALDH1A1 | |
| SCHEMBL21074600 | 0.85 | CYP2C9 (0.38) | MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL21074599 | 0.84 | CNR2 (0.33) | THRBMEN1ALDH1A1KMT2A | |
| SCHEMBL21074603 | 0.84 | CYP2C9 (0.37) | MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL19722398 | 0.83 | THRB (0.58) | THRBTHRARARBMEN1ALDH1A1 | |
| SCHEMBL19721952 | 0.83 | THRB (0.58) | THRBTHRARARBMEN1ALDH1A1 | |
| SCHEMBL21074609 | 0.83 | THRB (0.41) | THRBSPHK1THRAMEN1ALDH1A1 | |
| SCHEMBL21074684 | 0.82 | PPARG (0.32) | THRBSPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3495343-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC Corporation (JP) | 2019-06-12 | — | — | EP | disclosed |
| US-20190169502-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169502-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | PLD1, AP3D1, CCND1 | THRB 4725/4885SPHK1 362/4885THRA 4737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.